The aim of this double-blind, parallel group study was to rate during the last 60 min of clamp and total glucose requirements were evaluated. Nebivolol 5 mg once daily compare the effects of nebivolol and atenolol on blood pressure (BP) and insulin sensitivity in hypertensive was of an equivalent efficacy as atenolol 50 mg once daily at reducing supine and standing systolic and diaspatients with type II, non-insulin dependent diabetes mellitus (NIDDM). After a 4-week run-in period on platolic BP values. Neither ␤-blocker adversely affected carbohydrate metabolism in terms of insulin sensitivity, cebo, 30 patients (14 males and 16 females) aged 43 to 69 years, with stable NIDDM and mild to moderate whole body glucose utilization, HbA 1c and 24-h urinary C-peptide excretion. No significant changes in choleshypertension (DBP у у у95 and Ͻ Ͻ Ͻ116 mm Hg) were randomised to receive either nebivolol 5 mg or atenolol 50 mg, terol (total, high density and low density lipoprotein) and triglycerides plasma levels were observed with both both administered once daily for 6 months. At the end of the placebo and the active treatment periods, supine ␤-blockers. These findings indicate that, in hypertensive patients with NIDDM, ie, in subjects who have estaband standing BP was measured, 24-h urinary C-peptide, HbA 1c , plasma glucose and lipid levels were evaluated lished insulin resistance, treatment with nebivolol and atenolol neither further deteriorated insulin sensitivity and an euglycaemic hyperinsulinaemic clamp was performed to evaluate insulin sensitivity: glucose infusion nor adversely affected the lipid profile.
Introduction
insulinaemic clamp technique. 19 The frequent association of hypertension and type These studies showed that treatment with both ␤ 1 -II, non-insulin-dependent diabetes mellitus selective and non-selective ␤-adrenergic blockers (NIDDM) is well known and has been associated significantly increased insulin resistance and basal with a higher risk of cardiovascular complications. [1] [2] [3] plasma insulin, despite effectively lowering blood Insulin resistance has been suggested to provide a pressure (BP). 11, 12, 14, 18 These findings supported common pathophysiologic link between hypertenconcerns about using these drugs in diabetic sion and type II diabetes [4] [5] [6] and to contribute to assopatients, based on previous observations that treatciated altered plasma lipid profile that aggravates ment with ␤-blockers, and particularly non-selective the risk of coronary heart disease (CHD) in these ones, was associated with the induction of impaired patients. 6, 7 In addition, insulin resistance is conglucose tolerance, overt diabetes mellitus or exacersidered to be an independent risk factor for CHD. [7] [8] [9] bation of hyperglycaemia in patients with diabetes The suspicion that the pharmacological treatment mellitus. [20] [21] [22] [23] [24] of hypertension may worsen the insulin resistance However, the studies that evaluated the influence and associated metabolic abnormalities and contriof ␤-blockers on insulin sensitivity by the euglycaebute to the relative failure of antihypertensive treatmic hyperinsulinaemic clamp were conducted in ment to reduce coronary morbidity and mortality 10 hypertensive subjects without diabetes mellitus, led to a series of studies [11] [12] [13] [14] [15] [16] [17] [18] aimed at elucidating the whereas, to our knowledge, no data are available effects of commonly used antihypertensive drugs on about the assessment of insulin sensitivity by this technique during ␤-blocker therapy in subjects with NIDDM, ie, in the presence of a well established 19 to measure tissue sensitivity to iod on placebo), were candidates for enrolment. Exclusion criteria included: accelerating or maligexogenous insulin. The following parameters were derived: whole body glucose utilization (mg) nant hypertension, myocardial infarction or cerebrovascular accident within 6 months, bradycardia between 60 and 120 min of the test, glucose infusion velocity (mg/min) between 90 and 120 min and Ͻ60 b/min, atrial fibrillation or recurrent tachyarrhythmias requiring anti-arrhythmic therapy, mean glucose infusion rate (GIR) (mg/kg/min) between 90 and 120 min, derived from the formula: heart failure requiring therapy, sick sinus syndrome or A-V block greater than first degree, valvular disease of haemodynamic significance, chronic GIR = mean 60 : kg × 1000 × 0.2 obstructive lung disease, significant peripheral vascular disease, insulin dependent diabetes mellitus where mean = mean glucose infusion velocity (ml/h) or incidental insulin treatment within the past 3 between 90 and 120 min, 60 = min in an hour, months, diabetic ulceration, proliferative retino-1000 = mg in 1 g, 0.2 = infusion of 20% glucose. pathy or previous retinal laser therapy, nephropathy Plasma total cholesterol (TC), HDL-C, LDL-C and (urinary protein Ͼ500 mg/day, serum creatinine triglycerides were also determined using the enzy-Ͼ2.2 mg/dl), body mass index Ͼ32 kg/m 2 , pregnant matic method following ultracentrifugation and preor nursing women, disabling or terminal illness, hiscipitation of samples. tory of sensitivity or significant adverse reactions to Any adverse event that occurred during the trial ␤-blocker therapy.
period and that was mentioned by the patient either The trial was conducted in accordance with the spontaneously or after non-leading questioning ('did Declaration of Helsinki and its subsequent revisions.
you have any unwanted effect?') was recorded. Ethics Committee approval was obtained and the Patients' compliance to the therapy was evaluated patients gave their informed consent to participate by counting the residual tablets at each visit. in the trial.
No formal sample size calculation was performed; After a 4-week single-blind run-in period on plathe study population size of 30 patients was based cebo, during which existing antihypertensive medion practical considerations of patient recruitment cations were withdrawn, patients who fulfilled the rates. inclusion criteria were randomised to receive either Data are presented as means ± standard errors. nebivolol 5 mg or atenolol 50 mg, both administered Between treatment differences were statistically once daily for 6 months. Each patient's diet and analysed using the Mann-Whitney U-test. Within basic treatment with hypoglycaemic drugs were kept treatment changes were analysed using the Friedconstant during the trial. man test or the Wilcoxon matched pairs signedBefore enrolment, patients provided a medical rank test. and demographic history and underwent a physical All statistical tests were two-tailed and were interexamination, which included assessment of BP, preted at the 5% significance level. heart rate (HR), 12-lead ECG, fundoscopy, body weight, blood glucose, glycosylated haemoglobin
Results
(HbA 1c ) and other laboratory tests (complete blood cells count, transminases, alkaline phosphatase, Thirty patients, 14 males and 16 females, aged 43 to 69 years (mean age: 58.3 yr) were admitted to the bilirubin, ␥-GT, serum electrolytes, urea, creatinine, uric acid, urinalysis). These tests were repeated at study and none withdrew after randomisation. Fifteen were assigned to treatment with nebivolol 5 mg the end of the placebo run-in (week 0) and at study completion (week 24). Visits were scheduled at once daily and 15 received atenolol 50 mg once daily. weeks 2, 6, 12 and 24 throughout the double-blind treatment period; all assessments were made in the As shown in Table 1 , baseline demographic and clinical characteristics were not significantly differmorning, after an overnight fast and at trough plasma levels (ie, approximately 24 h after previous ent in the two groups of patients. Changes in BP induced by treatment with nebivolol or atenolol are dose of trial medications). shown in Table 2 . Both ␤-blocking agents markedly cholesterol (total, HDL, LDL) or triglycerides levels nor in mean 24-h urinary excretion of c-peptide, reduced BP values during the first 2 weeks of treatment and the improvements were sustained and albumin or glucose at the end of 6 months of treatment with either ␤-blockers (Table 3 ). The between enhanced at the end of the 24-week period assessment. None of the between treatment differences treatment differences were also non-significant. No consistent changes in blood chemistry or haemawas statistically significant (P Ͼ 0.05 Mann-Whitney U-test).
tology were observed. Adverse events were reported by three patients in Supine HR decreased by a mean of 10.4 and 14.4 b/min at weeks 2 and 24 in the nebivolol group and the nebivolol group (nightmares, abdominal pain and headache) and by two patients receiving atenoby 11.1 and 13.3 b/min in the atenolol group (Table  2) . Similar reductions were seen in standing HR. In lol (abdominal pain and asthenia). In all five patients the events were of mild intensity. No seriall cases the changes from baseline were statistically significant (P Ͻ 0.001, Friedman test). However, no ous adverse event was reported and no patient was removed from the trial due to side effects. All significant difference was found in the reductions between the two treatment groups (P Ͼ 0.05 Mannpatients adhered to the time schedule planned for the visits and patients' compliance with drug treatWhitney U-test).
No statistically significant changes in body weight ment was satisfactory. were observed in either group of patients (Table 3) . Table 4 shows the results of the euglycaemic hypDiscussion erinsulinaemic clamp test. Mean values for whole body glucose utilization decreased by a mean of The results of this study showed that nebivolol 5 mg once daily was of equivalent efficacy to atenolol 548 mg (2.6%) at the end of treatment with nebivolol compared to a mean increase of 189 (0.9%) in 50 mg once daily at reducing BP in hypertensive patients with concomitant NIDDM, which is in the atenolol group. Neither of these changes was statistically significant (P Ͼ 0.05, Wilcoxon matched keeping with previous results obtained with nebivolol in non-diabetic hypertensives. [34] [35] [36] [37] [38] [39] pairs signed-ranks test). The between treatment difference was also non-significant (P = 0.178, MannNeither nebivolol nor atenolol appeared to have any adverse effect on carbohydrate metabolism in Whitney U-test). The average glucose infusion rate during the last 30 min of the euglycaemic hyperterms of HbA 1c levels, 24-h excretion of glucose or Cpeptide, whole body glucose utilization and insulin insulinaemic clamp was also virtually unchanged between the end of the placebo run-in and week 24, sensitivity. The finding of a neutral effect of both ␤-blockers on insulin sensitivity is in contrast with suggesting that neither drug altered insulin sensitivity over the period tested.
previous observations. The ␤ 1 -selective atenolol and metoprolol were found to reduce whole-body insuThere were no newly occurring changes in HbA 1c , Table 2 Blood pressure and heart rate change from baseline (Week 0) after 2 and 24 weeks of treatment with nebivolol or atenolol *Mann-Whitney U-test for between treatment differences in changes from end of run-in. Note: BP and HR reductions from end of run-in to week 24 were highly significant within each treatment group (P Ͻ 0.001, Friedman test).
756 Table 3 Values of total cholesterol (TC), HDL-C, LDL-C, triglycerides (TG), glycosylated haemoglobin (HbA 1c ), 24-h urinary C-peptide, albumin and glucose, body weight at the end of the placebo run-in (week 0) and at the end of active treatment with nebivolol and atenolol (week 24) (means ± standard error) lin-mediated glucose uptake by 13% and 20% blocker therapy, 12, 40, 41 are directly and inversely related to plasma insulin concentrations. Nebivolol respectively and to decrease the insulin sensitivity index by 23% and 27%, with minor but significant and atenolol were both well tolerated. Only five patients (three with nebivolol and two with increases in HbA 1c and fasting blood glucose. 11 Although the most pronounced changes in insulinatenolol) reported adverse events. In each case there were mild events, that never required withdrawal mediated glucose uptake was observed with the non-selective propranolol, 12 the negative effect of from treatment.
In conclusion, the results of this study indicate ␤ 1 -selective ␤-blockers on insulin sensitivity was confirmed in another comparative study with atenothat nebivolol was as effective as atenolol in controlling BP levels in hypertensive patients with lol and the calcium channel blocker diltiazem: whereas the latter did not affect insulin-mediated NIDDM. In such patients, who clearly have insulin resistance, ␤ 1 -selective blockade did not influence glucose disposal, atenolol caused a 21% reduction.
11
All the above studies, however, regarded hyperinsulin sensitivity nor lipid profile. Since the cardioprotective potential of ␤-blockers is highly tensive patients without diabetes mellitus, whereas our findings refer to patients with NIDDM, ie, to subdesirable in diabetic hypertensives because of their enhanced cardiovascular risk, the lack of metabolic jects who clearly have already altered baseline insulin sensitivity. This suggests that the effect of ␤ 1 -adverse effect is of obvious clinical relevance in the treatment of these patients. adrenergic blockade on insulin sensitivity might be different according to the baseline characteristics of the patients, being less evident in the presence of 
